Eli Lilly and Company (LLY)
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
Eli Lilly and Novo Nordisk are leaders in fast-growing therapeutic areas. Both companies have excellent track records of innovations and solid results.
Eli Lilly's Growth And Challenges: A Cautious Buy
Eli Lilly announced impressive Q1 2024 financial results, with revenue surging by 26% YoY and exceeding expectations for earnings per share. The company raised its full-year 2024 revenue guidance and adjusted earnings per share guidance. While facing challenges with the price of its stock and supply chain issues, Eli Lilly anticipates significant increases in shipment volumes in the second half of 2024.
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
Eli Lilly and Novo Nordisk have generated incredible returns for investors in the past few years. The surging popularity of their weight loss treatments has produced a lot of bullishness.
Aristocrats in Disguise: 3 Blue-Chip Stocks With Stealth Growth Potential
Although there is no hard-and-fast rule about what constitutes a blue-chip stock, they all tend to have certain qualities. They are large, financially stable companies that have been through numerous business and economic cycles that proved their worth in the end.
Why Is Lilly (LLY) Up 4.5% Since Last Earnings Report?
Lilly (LLY) reported earnings 30 days ago. What's next for the stock?
Could Eli Lilly Be the Next to Join the Trillion-Dollar Club?
Eli Lilly sells two of the most sought-after treatments -- those prescribed for weight management. Mounjaro and Zepbound are driving double-digit earnings growth at the big pharma company.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
Eli Lilly stock could reach $1,001 per share, according to a Wall Street analyst from BMO Capital. Tirzepatide sales are off the charts but could be much higher if not for supply constraints.
Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.
Eli Lilly: Addressing Supply Challenges Should Accelerate Growth
Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of tirzepatide in the near- and possibly medium-term should only be limited by the quantities it can produce. Eli Lilly's competitive position in the obesity market is discussed in today's article along with the potential for growth acceleration in 2025 and 2026 versus current expectations for moderating growth rates.
Got $500? 3 Pharma Stocks to Buy and Hold Forever
Vertex Pharmaceuticals is in the midst of a major diversification plan. Eli Lilly's medicines for diabetes and obesity are incredibly hot sellers.
3 High-Flying Stocks That Could Soar Even More
Eli Lilly is just getting started with its powerful obesity drug and a loaded pipeline. It's not too late to invest in scorching-hot Novo Nordisk.
